procarbazine has been researched along with Cancer of Mediastinum in 59 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "9 years, range, 1-15 years) received the AIEOP-MH 1983 Hodgkin disease protocol of low-dose radiation therapy (20-25 Gy), with three cycles of adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) for children with early-stage and favorable disease, and with alternating cycles of an eight non-cross-resistant drug combination regimen (nitrogen mustard, vincristine, procarbazine, and prednisone [MOPP]/ABVD) for 6 months for those with bulky and unfavorable disease." | 5.07 | Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. ( Bontempi, N; Burnelli, R; Carli, M; Comelli, A; Di Tullio, MT; Pileri, S; Rosati, D; Sotti, G; Testi, AM; Vecchi, V, 1993) |
| "Combination chemotherapy consisting of cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) was administered to 5 patients with invasive lymphoepithelial thymoma." | 3.66 | Combination chemotherapy in invasive thymoma role of COPP. ( Evans, WK; Feld, R; Phillips, MJ; Simpson, WJ; Thompson, DM, 1980) |
| "Eighty patients presented with Hodgkin's disease and a mediastinal mass greater than one third the greatest chest diameter on chest radiograph." | 2.68 | Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. ( Bastian, AW; DeVita, VT; Duffey, PL; Glatstein, E; Hubbard, SM; Ihde, DC; Jaffe, ES; Longo, DL; Wilson, WH; Wittes, RE; Young, RC, 1997) |
| "We reviewed all reported cases of Burkitt's lymphoma and/or Burkitt's leukemia (BLL) occurring following therapy for Hodgkin's disease." | 2.39 | Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. ( Cooper, DL; Levy, A; Salloum, E; Tallini, G, 1996) |
| "This article reports a patient with Hodgkin's disease in remission after combined modality therapy who developed metastatic pulmonary osteosarcoma, subsequently found to originate in soft tissue of the mediastinum, within a field irradiated 11 years previously." | 2.37 | Mediastinal osteosarcoma with extension to lungs in a patient treated for Hodgkin's disease. ( Andres, DF; Catanese, J; Dorfman, HD; Dutcher, JP; Wiernik, PH, 1988) |
| "Reporting the first case of localized Hodgkin lymphoma treated with protontherapy in France." | 1.51 | Protontherapy versus best photon for mediastinal Hodgkin lymphoma: Dosimetry comparison and treatment using ILROG guidelines. ( Abbassi, LM; Arsène-Henry, A; Dendale, R; Goudjil, F; Kirova, YM, 2019) |
| "By October 2008, cardiac diseases (CD) had been diagnosed in 50 of 1,132 patients aged 15." | 1.36 | Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. ( Bölling, T; Brämswig, J; Bruch, C; Dieckmann, K; Dörffel, W; Heinecke, A; Kotthoff, S; Pötter, R; Riepenhausen, M; Schellong, G; Vogt, J, 2010) |
| "Of the 13 cases, 5 were Hodgkin's disease (HD), and 8 were non-Hodgkin's lymphoma (NHL)." | 1.33 | [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "Treatment strategies in Hodgkin's disease have an impact on different risk factors." | 1.32 | Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. ( Dieckmann, K; Heinzl, H; Hofmann, J; Pötter, R; Schellong, G; Wagner, W, 2003) |
| "Management of Hodgkin's disease (HD) and large mediastinal adenopathy (LMA) usually includes intensive chemotherapy (CT) with or without radiation therapy (XT) regardless of stage." | 1.29 | Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. ( Allen, PK; Besa, P; Cabanillas, F; Cox, JD; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, A; Swan, F, 1994) |
| "Between 1980 and 1988, 48 patients with Hodgkin's disease who had large mediastinal masses were treated at Stanford University." | 1.29 | Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy. ( Behar, RA; Hoppe, RT; Horning, SJ, 1993) |
| "The authors concluded that in pediatric Hodgkin's disease, a MM with a MMR greater than or equal to 0." | 1.28 | Mediastinal masses in children with Hodgkin's disease. An analysis of the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania experience. ( D'Angio, GJ; Goldwein, JW; Lange, B; Maity, A, 1992) |
| "A 30 years old man having Hodgkin's disease was treated successfully by means of chemotherapy and radiotherapy." | 1.27 | [Myocardial infarction after mediastinal radiotherapy of Hodgkin's disease]. ( Callén, L; Fuertes, MA; Gutiérrez, M; Peleato, A; Poderós, C; Polo, J; Rodrigo, G; Tres, A, 1984) |
| "Of 157 patients with Hodgkin's disease treated between 1970 and 1981 an assessment of the clinical course was possible in 134 cases." | 1.27 | [Recurrence in Hodgkin's disease: incidence, therapy and prognosis. (Experience with 134 patients)]. ( Denz, H; Huber, H; Lechleitner, M; Peer, L; Peschel, C, 1983) |
| "There was no significant difference in recurrence rates between patients without mediastinal mass and patients with a small mass, and in these patients adjuvant chemotherapy MOPP after radiotherapy showed an evident benefit in reducing the relapse rate." | 1.27 | Prognostic significance of large mediastinal involvement in Hodgkin's disease. ( Baccarani, M; Cantore, M; Dominici, G; Emiliani, E; Faedi, M; Fiacchini, M; Frezza, G; Lauria, F; Mazza, P; Sciascia, R, 1983) |
| "Of 244 patients with Hodgkin's disease, 126 (52%) had an abnormal mediastinum." | 1.27 | Observations on the treatment of mediastinal masses in Hodgkin's disease emphasizing site of failure. ( Chan, PY; Hintz, BL; Kagan, AR; McMahon, J; Nussbaum, H; Rao, AR; Ryoo, MC; Wollin, M, 1987) |
| "A case of recurrent Hodgkin's disease of the "sarcomatoid" or "syncytial variant" type was seen that occurred as an extension from the mediastinum to a previously uninvolved extranodal site (breast) and pericardium after treatment of classical nodular sclerosing Hodgkin's disease based in the lymph nodes." | 1.27 | Recurrent "syncytial variant" of Hodgkin's disease: an immunohistologic diagnosis. ( Blaustein, JC; Lewkow, L, 1987) |
| "94 patients with Hodgkin's disease PS I or II, treated during the period 1969-78 and followed until death, or from 33 to 136 months after initiation of therapy, were analysed." | 1.27 | Prognostic significance of tumour burden in Hodgkin's disease PS I and II. ( Nissen, NI; Specht, L, 1986) |
| "Thymic hyperplasia is a poorly understood, apparently benign process that may be confused with recurrent lymphoma." | 1.27 | Thymic hyperplasia masquerading as recurrent Hodgkin's disease: case report and review of the literature. ( Edington, H; Longo, DL; Pass, H; Roth, JA; Salwitz, J, 1986) |
| "A case of thymic Hodgkin's disease presenting with an anterior mediastinal mass is reported." | 1.27 | Cystic degeneration of thymic Hodgkin's disease following radiation therapy. ( Haas, A; Kim, HC; Lewis, R; Nosher, J; Sweeney, W, 1985) |
| "47 patients with advanced Hodgkin's disease (stage IIIB or IV) and mediastinal involvement, treated during the period 1969-78 and followed till death or from 36 to 126 months after initiation of therapy, were analysed." | 1.27 | Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease. ( Nissen, NI; Specht, L; Walbom-Jørgensen, S, 1985) |
| "A 27 year old man with Hodgkin's disease experienced three separate episodes of chest pain, each occurring on the sixth day of a cycle of mustargen, oncovin, procarbazine, prednisone (MOPP) combination chermotherapy." | 1.26 | Unusual cardiac reaction to chemotherapy following mediastinal irradiation in a patient with Hodgkin's disease. ( Greenwald, ES; Grossman, J; Weinstein, P, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (45.76) | 18.7374 |
| 1990's | 15 (25.42) | 18.2507 |
| 2000's | 9 (15.25) | 29.6817 |
| 2010's | 5 (8.47) | 24.3611 |
| 2020's | 3 (5.08) | 2.80 |
| Authors | Studies |
|---|---|
| Farrugia, MK | 1 |
| Vargo, JA | 1 |
| Zawati, I | 1 |
| Adouni, O | 1 |
| Finetti, P | 1 |
| Manai, M | 2 |
| Gamoudi, A | 1 |
| Birnbaum, D | 1 |
| Bertucci, F | 1 |
| Mezlini, A | 1 |
| O'Kelly, B | 1 |
| McGettrick, P | 1 |
| Angelov, D | 1 |
| Fay, M | 1 |
| McGinty, T | 1 |
| Cotter, AG | 1 |
| Sheehan, G | 1 |
| Lambert, JS | 1 |
| Abbassi, LM | 1 |
| Goudjil, F | 1 |
| Arsène-Henry, A | 1 |
| Dendale, R | 1 |
| Kirova, YM | 1 |
| Advani, RH | 1 |
| Hong, F | 1 |
| Fisher, RI | 1 |
| Bartlett, NL | 1 |
| Robinson, KS | 1 |
| Gascoyne, RD | 1 |
| Wagner, H | 1 |
| Stiff, PJ | 1 |
| Cheson, BD | 1 |
| Stewart, DA | 1 |
| Gordon, LI | 1 |
| Kahl, BS | 1 |
| Friedberg, JW | 1 |
| Blum, KA | 1 |
| Habermann, TM | 1 |
| Tuscano, JM | 1 |
| Hoppe, RT | 4 |
| Horning, SJ | 2 |
| Metwally, H | 1 |
| Courbon, F | 1 |
| David, I | 1 |
| Filleron, T | 1 |
| Blouet, A | 1 |
| Rives, M | 1 |
| Izar, F | 1 |
| Zerdoud, S | 1 |
| Plat, G | 1 |
| Vial, J | 1 |
| Robert, A | 1 |
| Laprie, A | 1 |
| Schellong, G | 2 |
| Riepenhausen, M | 1 |
| Bruch, C | 1 |
| Kotthoff, S | 1 |
| Vogt, J | 1 |
| Bölling, T | 1 |
| Dieckmann, K | 2 |
| Pötter, R | 2 |
| Heinecke, A | 1 |
| Brämswig, J | 1 |
| Dörffel, W | 1 |
| Dunleavy, K | 1 |
| Grant, C | 1 |
| Eberle, FC | 1 |
| Pittaluga, S | 1 |
| Jaffe, ES | 2 |
| Wilson, WH | 2 |
| Au, WY | 1 |
| Ma, SK | 1 |
| Wan, TS | 1 |
| Wang, EP | 1 |
| Lau, TC | 1 |
| Kwong, YL | 1 |
| Hofmann, J | 1 |
| Heinzl, H | 1 |
| Wagner, W | 1 |
| Schneider, T | 1 |
| Tóth, E | 1 |
| Molnár, Z | 1 |
| Várady, E | 1 |
| Deák, B | 1 |
| Horváth, A | 1 |
| Horváth, GI | 1 |
| Eid, H | 1 |
| Schneider, K | 1 |
| Lovey, J | 1 |
| Keresztes, S | 1 |
| Esik, O | 1 |
| Lengyel, Z | 1 |
| Rosta, A | 1 |
| Zhen, ZJ | 1 |
| Sun, XF | 1 |
| Xia, Y | 1 |
| Wang, ZH | 1 |
| Ling, JY | 1 |
| Aleman, BM | 1 |
| Raemaekers, JM | 1 |
| Tomiŝiĉ, R | 1 |
| Baaijens, MH | 1 |
| Bortolus, R | 1 |
| Lybeert, ML | 1 |
| van der Maazen, RW | 1 |
| Girinsky, T | 1 |
| Demeestere, G | 1 |
| Lugtenburg, P | 1 |
| Lievens, Y | 1 |
| de Jong, D | 1 |
| Pinna, A | 1 |
| Henry-Amar, M | 1 |
| Eich, HT | 1 |
| Gossmann, A | 1 |
| Engert, A | 1 |
| Kriz, J | 1 |
| Bredenfeld, H | 1 |
| Hansemann, K | 1 |
| Skripnitchenko, R | 1 |
| Brillant, C | 1 |
| Pfistner, B | 1 |
| Staar, S | 1 |
| Diehl, V | 2 |
| Müller, RP | 1 |
| Valdivieso, M | 1 |
| Cabanillas, F | 3 |
| Keating, M | 1 |
| Barkley, HT | 1 |
| Murphy, WK | 1 |
| Burgess, MA | 1 |
| Frazier, H | 1 |
| Chen, T | 1 |
| Bodey, GP | 1 |
| Tres, A | 1 |
| Fuertes, MA | 1 |
| Callén, L | 1 |
| Poderós, C | 1 |
| Rodrigo, G | 1 |
| Peleato, A | 1 |
| Polo, J | 1 |
| Gutiérrez, M | 1 |
| Robinson, B | 1 |
| Kingston, J | 1 |
| Nogueira Costa, R | 1 |
| Malpas, JS | 1 |
| Barrett, A | 1 |
| McElwain, TJ | 1 |
| Denz, H | 1 |
| Lechleitner, M | 1 |
| Peschel, C | 1 |
| Peer, L | 1 |
| Huber, H | 1 |
| Mazza, P | 1 |
| Lauria, F | 1 |
| Sciascia, R | 1 |
| Emiliani, E | 1 |
| Fiacchini, M | 1 |
| Baccarani, M | 1 |
| Frezza, G | 1 |
| Dominici, G | 1 |
| Cantore, M | 1 |
| Faedi, M | 1 |
| Bacci, M | 1 |
| Cavaliere, A | 1 |
| Amorosi, A | 1 |
| Hagemeister, FB | 5 |
| Fuller, LM | 5 |
| Sullivan, JA | 1 |
| North, L | 1 |
| Velasquez, W | 1 |
| Conrad, FG | 1 |
| McLaughlin, P | 3 |
| Butler, JJ | 2 |
| Shullenberger, CC | 1 |
| Kantor, G | 1 |
| Cosset, JM | 1 |
| Masselot, J | 1 |
| Coleman, CN | 1 |
| Cox, RS | 1 |
| Rosenberg, SA | 1 |
| Kaplan, HS | 1 |
| Mauch, P | 1 |
| Hellman, S | 2 |
| Evans, WK | 1 |
| Thompson, DM | 1 |
| Simpson, WJ | 1 |
| Feld, R | 1 |
| Phillips, MJ | 1 |
| Brusamolino, E | 1 |
| Lazzarino, M | 1 |
| Orlandi, E | 1 |
| Canevari, A | 1 |
| Morra, E | 1 |
| Castelli, G | 1 |
| Alessandrino, EP | 1 |
| Pagnucco, G | 1 |
| Astori, C | 1 |
| Livraghi, A | 1 |
| Preti, A | 1 |
| Swan, F | 1 |
| Rodriguez, A | 1 |
| Besa, P | 1 |
| Cox, JD | 1 |
| Allen, PK | 1 |
| Behar, RA | 1 |
| Vecchi, V | 1 |
| Pileri, S | 1 |
| Burnelli, R | 1 |
| Bontempi, N | 1 |
| Comelli, A | 1 |
| Testi, AM | 1 |
| Carli, M | 1 |
| Sotti, G | 1 |
| Rosati, D | 1 |
| Di Tullio, MT | 1 |
| Gosselin, M | 1 |
| Podgorsak, EB | 1 |
| Evans, MD | 1 |
| Pla, M | 1 |
| Shenouda, G | 1 |
| Grigoraki, V | 1 |
| Lilienthal, F | 1 |
| Touboul, E | 1 |
| Gabarre, J | 1 |
| Binet, JL | 1 |
| Merle-Béral, H | 1 |
| Salloum, E | 1 |
| Tallini, G | 1 |
| Levy, A | 1 |
| Cooper, DL | 1 |
| Longo, DL | 2 |
| Glatstein, E | 1 |
| Duffey, PL | 1 |
| Young, RC | 1 |
| Ihde, DC | 1 |
| Bastian, AW | 1 |
| Wittes, RE | 1 |
| Hubbard, SM | 1 |
| DeVita, VT | 1 |
| Bieri, S | 1 |
| Roggero, E | 1 |
| Zucca, E | 1 |
| Bertoni, F | 1 |
| Pianca, S | 1 |
| Sanna, P | 1 |
| Pedrinis, E | 1 |
| Bernier, J | 1 |
| Cavalli, F | 1 |
| Kondrat'eva, NE | 1 |
| Demina, EA | 1 |
| Nivinskaia, MM | 1 |
| Iur'eva, TV | 1 |
| Unukova, EN | 1 |
| Paches, LR | 1 |
| Pirogova, NA | 1 |
| Elconin, JH | 1 |
| Roberts, KB | 1 |
| Rizzieri, DA | 1 |
| Vermont, C | 1 |
| Clough, RW | 1 |
| Kim, C | 1 |
| Dodge, RK | 1 |
| Prosnitz, LR | 1 |
| Weihrauch, MR | 1 |
| Re, D | 1 |
| Scheidhauer, K | 1 |
| Ansén, S | 1 |
| Dietlein, M | 1 |
| Bischoff, S | 1 |
| Bohlen, H | 1 |
| Wolf, J | 1 |
| Schicha, H | 1 |
| Tesch, H | 1 |
| Madoc-Jones, H | 1 |
| Gamble, JF | 1 |
| Sullivan, MP | 1 |
| Fernandez, CH | 1 |
| Gehan, EA | 1 |
| Weinstein, P | 1 |
| Greenwald, ES | 1 |
| Grossman, J | 1 |
| Maity, A | 1 |
| Goldwein, JW | 1 |
| Lange, B | 1 |
| D'Angio, GJ | 1 |
| Ganesan, TS | 1 |
| Oza, A | 1 |
| Perry, N | 1 |
| D'Ardenne, J | 1 |
| Arnott, S | 1 |
| Stansfeld, AG | 1 |
| Shand, WS | 1 |
| Wrigley, PF | 1 |
| Lister, TA | 1 |
| Zeymer, U | 1 |
| Hirschmann, WD | 1 |
| Neuhaus, KL | 1 |
| Djulbegovic, B | 1 |
| Hendler, FJ | 1 |
| Hamm, J | 1 |
| Hadley, T | 1 |
| Woodcock, TM | 1 |
| Vila, S | 1 |
| Zerga, M | 1 |
| Villegas, A | 1 |
| Somoza, N | 1 |
| Baĭsogolov, GD | 1 |
| Afanasova, NV | 1 |
| Shakhtarina, SV | 1 |
| Ferrant, A | 1 |
| Hamoir, V | 1 |
| Binon, J | 1 |
| Michaux, JL | 1 |
| Sokal, G | 1 |
| Catanese, J | 1 |
| Dutcher, JP | 1 |
| Dorfman, HD | 1 |
| Andres, DF | 1 |
| Wiernik, PH | 1 |
| North, LB | 2 |
| Sullivan-Halley, JA | 1 |
| Velasquez, WS | 1 |
| Willett, CG | 1 |
| Linggood, RM | 1 |
| Leong, JC | 1 |
| Miketic, LM | 1 |
| Stracher, MA | 1 |
| Skates, SJ | 1 |
| Kushner, DC | 1 |
| Ryoo, MC | 1 |
| Kagan, AR | 1 |
| Wollin, M | 1 |
| Nussbaum, H | 1 |
| Chan, PY | 1 |
| Hintz, BL | 1 |
| Rao, AR | 1 |
| McMahon, J | 1 |
| Blaustein, JC | 1 |
| Lewkow, L | 1 |
| Specht, L | 2 |
| Nissen, NI | 2 |
| Edington, H | 1 |
| Salwitz, J | 1 |
| Roth, JA | 1 |
| Pass, H | 1 |
| Kim, HC | 1 |
| Nosher, J | 1 |
| Haas, A | 1 |
| Sweeney, W | 1 |
| Lewis, R | 1 |
| Walbom-Jørgensen, S | 1 |
| Leslie, NT | 1 |
| Mauch, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease[NCT00003389] | Phase 3 | 854 participants (Actual) | Interventional | 1999-06-17 | Completed | ||
| Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease[NCT00002462] | Phase 3 | 615 participants (Actual) | Interventional | 1989-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival is defined as the time from randomization to death or last known alive. The 5-year survival rate is the probability a patient survives 5 years. (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.88 |
| Arm B (Stanford V) | 0.88 |
"Failure-free survival is defined as the time from randomization to the earlier of progression/relapse or death. The 5-year failure-free survival is the probability a patient is failure-free and survives 5 years.~Progression is defined as an increase in size of 25% of the sum of the products of the pretreatment measurements or appearance of new lesions. Significant enlargement of the liver or spleen is evidence of progression. A significant increase in size is defined as > 2.0 cm in distance between costal margin and the inferior margin of either organ.~Relapse is defined as the re-appearance of any clinical evidence of Hodgkin's disease in a patient who has had a complete response. Relapse for partial responders is defined as progressive disease relative to disease status during the partial remission." (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.74 |
| Arm B (Stanford V) | 0.71 |
Number of patients who developed second primary cancers (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | participants (Number) |
|---|---|
| Arm A (ABVD) | 15 |
| Arm B (Stanford V) | 19 |
5 reviews available for procarbazine and Cancer of Mediastinum
| Article | Year |
|---|---|
Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease | 2012 |
Modality treatment in adult stage I-II Hodgkin's disease with large mediastinal masses: study of 30 cases and review of the literature.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female | 1993 |
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide | 1996 |
Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1999 |
Mediastinal osteosarcoma with extension to lungs in a patient treated for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hodgkin Disease; H | 1988 |
8 trials available for procarbazine and Cancer of Mediastinum
| Article | Year |
|---|---|
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant | 2015 |
Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2007 |
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgki
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2007 |
Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Female; Hodgkin Disease; | 1981 |
Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Pr | 1993 |
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Combined Modali | 1997 |
New assessment of the prognostic significance of histopathology in Hodgkin's disease for laparotomy-negative stage I and stage II patients.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hodgkin Disease; Hum | 1977 |
The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Follow-Up Studies; Hodgkin | 1988 |
46 other studies available for procarbazine and Cancer of Mediastinum
| Article | Year |
|---|---|
What to Do With Deauville 3 Interim Positron Emission Tomography/Computed Tomography Response in a Young Woman With Classic Unfavorable Hodgkin's Lymphoma: To Irradiate or Not to Irradiate?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Dox | 2020 |
Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2020 |
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2020 |
Protontherapy versus best photon for mediastinal Hodgkin lymphoma: Dosimetry comparison and treatment using ILROG guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; | 2019 |
Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin's disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Doxo | 2011 |
Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2010 |
Concurrent mediastinal B cell lymphoma and chronic myeloid leukemia with an unusually favorable response to chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clone Cells; Combined Modal | 2003 |
Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pres | 2003 |
[Treatment of primary mediastinal large B-cell lymphomas].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleo | 2004 |
[Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Daca | 2006 |
Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carcinoma, Bronch | 1984 |
[Myocardial infarction after mediastinal radiotherapy of Hodgkin's disease].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1984 |
Chemotherapy and irradiation in childhood Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chlorambucil; C | 1984 |
[Recurrence in Hodgkin's disease: incidence, therapy and prognosis. (Experience with 134 patients)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Mechlorethamine; Mediastina | 1983 |
Prognostic significance of large mediastinal involvement in Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female | 1983 |
Procarbazine hydrochlorate carcinogenesis in Osborne-Mendel rats.
Topics: Animals; Carcinogens; Carcinoma; Female; Lung Neoplasms; Male; Mammary Neoplasms, Experimental; Medi | 1984 |
[Advantages of thoracic CT scanning in the treatment of mediastinal lymphomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma; Mechlorethamine | 1982 |
The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lymph No | 1982 |
Supradiaphragmatic Hodgkin's disease: is there a role for MOPP chemotherapy in patients with bulky mediastinal disease?
Topics: Drug Therapy, Combination; Hodgkin Disease; Humans; Mechlorethamine; Mediastinal Neoplasms; Predniso | 1980 |
Combination chemotherapy in invasive thymoma role of COPP.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Co | 1980 |
Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Combin | 1994 |
Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1994 |
Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1993 |
A technique using parallel-opposed high energy electron beams for reirradiation of tumors near the spinal cord.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Mechloretham | 1993 |
[Treatment of local Hodgkin's disease with massive mediastinal involvement].
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Cyclophosphamide; D | 2000 |
Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2000 |
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cy | 2001 |
Unusual cardiac reaction to chemotherapy following mediastinal irradiation in a patient with Hodgkin's disease.
Topics: Adult; Drug Therapy, Combination; Heart; Hodgkin Disease; Humans; Male; Mechlorethamine; Mediastinal | 1976 |
Mediastinal masses in children with Hodgkin's disease. An analysis of the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania experience.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Ad | 1992 |
Management of stage II Hodgkin's disease: 15 years experience at St. Bartholomew's Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1992 |
Left main coronary stenosis by a mediastinal lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Coronary Disease; Cyclophosphamide; Humans; Lymphoma | 1992 |
Residual mediastinal mass after treatment of Hodgkin's disease: a decision analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Decision Trees; Hodgkin D | 1992 |
[Late recurrences in Hodgkin's disease: description of a case after 14 yr of continuous remission].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1991 |
[Treatment of Hodgkin's disease with lesions of the mediastinal lymph nodes and involvement in pulmonary processes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Hodgkin | 1990 |
Combined modality therapy for mediastinal Hodgkin's disease. Prognostic significance of constitutional symptoms and size of disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Comb | 1985 |
Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fert | 1989 |
Regression of mediastinal Hodgkin disease after therapy: evaluation of time interval.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Follow-Up Studies | 1987 |
Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Dose-Response Relationship | 1988 |
Observations on the treatment of mediastinal masses in Hodgkin's disease emphasizing site of failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 1987 |
Recurrent "syncytial variant" of Hodgkin's disease: an immunohistologic diagnosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hodgkin Disease; Hu | 1987 |
Prognostic significance of tumour burden in Hodgkin's disease PS I and II.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Mechlorethamine; Mediastina | 1986 |
Thymic hyperplasia masquerading as recurrent Hodgkin's disease: case report and review of the literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Hodgkin Disease | 1986 |
Cystic degeneration of thymic Hodgkin's disease following radiation therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cysts; Diagnosis, Differential; Hodgkin Disea | 1985 |
Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Hodgkin Disease; Humans; Mechlore | 1985 |
Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 1985 |
The management of stage II Hodgkin's disease with a large mediastinal mass: a prospective program emphasizing irradiation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; | 1985 |